Why the study?
Does reteplase reduce 30-day mortality compared to accelerated tPA in patients with acute myocardial infarction, based on the open-artery hypothesis?
Population
Patients with acute myocardial infarction
Comparison
Reteplase (rPA) vs Accelerated tissue plasminogen activator (tPA)
Design
Review
Follow-up
30 days
Authors
Loading...
Challenges the open-artery hypothesis as mortality surrogate; leaves open optimal thrombolytic selection in acute MI.
Does reteplase reduce 30-day mortality compared to accelerated tPA in patients with acute myocardial infarction, based on the open-artery hypothesis?
The lack of mortality difference between reteplase and tPA in GUSTO-III challenges the open-artery hypothesis that 90-minute TIMI grade 3 flow is a strong predictor of mortality differences between thrombolytic agents.
Kathleen A. Stringer (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: